ArticleFrontiers in pharmacology2026
Association between dexmedetomidine administration and 28-day mortality in critically ill patients with ventilator-associated pneumonia.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ventilator-associated pneumonia (VAP) is a frequent intensive care unit (ICU) complication linked to prolonged ventilation, extended ICU and hospital stays, increased costs, and higher mortality. Current guidelines recommend light sedation with dexmedetomidine (DEX) or propofol for ventilated adults. Although DEX has shown anti-inflammatory effects in animal models, its impact on VAP outcomes remains unclear. This study aims to investigate the association between DEX administration and 28-day mortality in patients with VAP. Methods: This retrospective cohort study enrolled VAP patients from the Medical Information Mart for Intensive Care (MIMIC) (version 3.0) database, categorized into DEX-treated and non-DEX groups during ICU admission. The primary outcome was 28-day mortality. Secondary outcomes included ICU, in-hospital mortality. Kaplan-Meier (KM) survival curves with log-rank tests and Cox proportional hazards models evaluated the association between DEX use and mortality outcomes. To adjust for baseline differences, 1:1 propensity score matching (PSM) was applied. Interaction and subgroup analyses further examined result consistency. Results: Data from 1,753 patients were analyzed, comprised 901 in the DEX group and 852 in the non-DEX group. The analysis of KM curves revealed a significantly lower 28-day mortality rate in the DEX group compared to the non-DEX group. After adjusting for multiple confounding factors, the Cox regression model demonstrated a significant protective impact of DEX-use on the risk of 28-day mortality in patients with VAP, with hazard ratios (HR) of 0.54 (95% confidence interval (CI): 0.43-0.67, p < 0.001). PSM analysis confirmed these results, showing HR of 0.81 (95% CI: 0.65-0.99, p = 0.044). No interactions were observed between DEX-use and 28-day mortality across stratified variables. Conclusion: DEX administration during the ICU stays was associated with improved outcomes in critically ill patients with VAP. The results need to be verified in randomized controlled trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.